Table 3.
Summary of Oncolytic Vectors and Clinical Trials
| HSV Strain | Genetic Modification | Therapeutic Transgenes | Stage | Clinical Indications | Ref. |
|---|---|---|---|---|---|
| dlsptk | tk deletion | none | Preclinical | [148, 240] | |
| hrR3 | UL39 disruption (large RR subunit) | none | Preclinical | [155, 241, 242] | |
| HSV1716 | Deletion in both copies of ICP34.5 | none | Human clinical trials Phase I (recruitment not yet open) | Glioma, melanoma, head-and-neck cancer. Non-CNS solid tumours | [167, 169, 170, 243, 244] |
| R3616 | Deletion in both copies of ICP34.5 | none | Preclinical | [151, 157] | |
| R4009 | Stop codon in both copies of ICP34.5 | none | Preclinical | [151, 157] | |
| G207 | Deletion in both copies of ICP34.5 + disruption of UL39 | none | Human clinical trials phase I, IB, and II | Recurrent brain cancer (glioma, astrocytoma, glioblastoma | [161-165, 245, 246] |
| MGH-1 | Deletion in both copies of ICP34.5 + disruption of UL39 | none | Preclinical | [149, 166] | |
| MGH-2 | Deletion in both copies of ICP34.5 + disruption of UL39 | CYP2B1 and shiCE | Preclinical | [190] | |
| R7020 (NV1020) | Deletion in one copy of ICP34.5 + tk under ICP4 promoter control + deletion in UL24, 55 and 56 | none | Human clinical trials phase I and II | Liver, metastases derived from colorectal cancer. | [121, 122, 176, 177] |
| G47Δ | Deletion in both copies of ICP34.5 + disruption of UL39 | none | Preclinical | [144] | |
| Myb34.5 | Deletion in both copies of ICP34.5 + disruption of UL39 + insertion of an ICP34.5 gene under the control of the B-myc promoter | none | Preclinical | [247, 248] | |
| DF3γ34.5 | Deletion in both copies of ICP34.5 + insertion of an ICP34.5 gene under the control of the DF3/MUC1 promoter | none | Preclinical | [139, 249] | |
| HF10 | Spontaneous generation of HSC-1 variant | none | Human clinical trials | [215, 216] | |
| NV1042 | HSV-1/HSV-2 intertypic recombinant + contains only one ICP34.5 copy | Murine IL-12 | Preclinical | [192-195] | |
| OncoVexGM-CSF | Deletion in both copies of ICP34.5 + deletion of ICP47 | GM-CSF | Phase II/III | Breast cancer, head-and-neck cancer, melanoma | [160, 250] |
| RAMBO | Deletion in both copies of ICP34.5 + UL39 disruption | IE4/5 prom-Vstat120 | Preclinical | [214] | |
| NP2 enkephalin expressing vector | Deletions in ICP4, 27, 22 and 47 | human preproenkephalin | Phase I | Chronic pain from terminal cancer | [38, 39] |